-
1
Neuroblastoma—A Neural Crest Derived Embryonal Malignancy
Published 2019-01-01Subjects: Get full text
Article -
2
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults
Published 2021-01-01Subjects: Get full text
Article -
3
Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations
Published 2022-06-01Subjects: Get full text
Article -
4
Deciphering the dual roles of PHD finger proteins from oncogenic drivers to tumor suppressors
Published 2024-05-01Subjects: Get full text
Article -
5
Genomic alterations and molecular subtypes of gastric cancers in Asians
Published 2016-05-01Subjects: Get full text
Article -
6
Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention
Published 2023-12-01Subjects: Get full text
Article -
7
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients
Published 2021-01-01Subjects: Get full text
Article -
8
Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
Published 2020-11-01Subjects: Get full text
Article -
9
Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer
Published 2025-02-01Subjects: Get full text
Article -
10
-
11
Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
Published 2021-05-01Subjects: Get full text
Article -
12
HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies
Published 2023-12-01Subjects: Get full text
Article -
13
Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
Published 2021-06-01Subjects: Get full text
Article -
14
Patient‐Initiated Nationwide Survey on Testing for Actionable Oncogenic Drivers in Non‐Small Cell Lung Cancer in Japan
Published 2024-11-01Subjects: “…actionable oncogenic drivers…”
Get full text
Article -
15
Dynamic monitoring serum tumor markers to predict molecular features of EGFR‐mutated lung cancer during targeted therapy
Published 2022-08-01Subjects: Get full text
Article -
16
ATM inhibition blocks glucose metabolism and amplifies the sensitivity of resistant lung cancer cell lines to oncogene driver inhibitors
Published 2023-11-01Subjects: Get full text
Article -
17
Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC
Published 2023-06-01Subjects: Get full text
Article -
18
CaDrA: A Computational Framework for Performing Candidate Driver Analyses Using Genomic Features
Published 2019-02-01Subjects: “…oncogenic driver analysis…”
Get full text
Article -
19
-
20